4TH ANNUAL
IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM
1ST JUNE 2018 | WALDORF ASTORIA CHICAGO HOTEL | USA

CONFERENCE GUIDE
www.sachsforum.com
SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:

4TH IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM

1ST JUNE 2018
WALDORF ASTORIA CHICAGO HOTEL
UNITED STATES

Sachs Associates are delighted to welcome you to the 4th Annual Immuno-Oncology BD&L and Investment Forum, taking place on the first day of ASCO. The 4th IOBDLI Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 200 delegates and around 20 presentations by listed and private biotechnology companies seeking licensing & investment.

Plenary Panels will include:

• Industry Roundtable: Pharma-Biotech Pipeline
• DealMaking and M&A
• Latest Developments in IO & Combination Therapies
• Cancer Vaccines and Neo Antigens: Evaluating Latest Progress
• Advances in Cell & Gene Therapies
• Early Stage Innovation
• Investor Roundtable

GENERAL INFORMATION

• The registration desk will be open from 7.20 am, although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.
• Networking at the forum is facilitated by our online One-2-One meeting system, which is available to all participants.

REQUEST FOR PRESENTATIONS

Please use the agenda to mark off presentations that you are interested in and email your request to Silvia@sachsforum.com after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Silver Sponsor:

Supported by:
EVENTS DIARY

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on Silvia@sachsforum.com.

18TH ANNUAL
BIOTECH IN EUROPE FORUM
4TH – 5TH OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

18th Annual BEF Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 650 delegates and over 100 presenting companies plus presentations by seed companies. The forum will be held for the fifth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The programme will feature number of plenary panels/workshops covering BD & Licensing in the main therapeutic areas.

6TH ANNUAL
MEDTECH & DIGITAL HEALTH FORUM
5TH OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

This year we will be holding our 6th Annual MT&DH Forum on the second day of our 18th Annual BEF Forum, on the 5th of October at the Congress Center Basel. The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 250 delegates and 25 presenting companies, plus around 20 presentations by seed companies.

2ND ANNUAL
NEUROSCIENCE INNOVATION FORUM
6TH JANUARY 2019 • MARINE’S MEMORIAL CLUB • SAN FRANCISCO • USA

Building on the success of our 1st Neuroscience Innovation Forum we are pleased to announce the 2nd Neuroscience Innovation Forum that will take place at Marines’ Memorial Club on the 6th of January 2019, a day before the JP Morgan meeting. The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma and medtech/digital health companies. We anticipate around 250 delegates and 20 company presentations by established and emerging companies.

ONLINE ONE-2-ONE MEETING SYSTEM AVAILABLE AT ALL SACHS EVENTS

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides all delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.
KEYNOTE SPEAKERS:

**RA Capital Management, LLC**

**Peter Kolchinsky**  
Portfolio Manager & Managing Director

Peter Kolchinsky is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a Board Member for various public and privately held companies, including Dicerna Pharmaceuticals, Inc. and Wave Life Sciences Ltd. Peter also leads the firm’s outreach and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policy makers, and industry. He authored “The Entrepreneur’s Guide to a Biotech Startup” and served on the Board of Global Science and Technology for the National Academy of Sciences. Peter holds a BS from Cornell University and a PhD in Virology from Harvard University.

**BerGenBio ASA**

**Richard Godfrey**  
Chief Executive Officer

Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years’ industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in R&D and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University.
**Eli Lilly & Co.**

**Andrew Hass**
Senior Advisor, Oncology External Innovation

Andrew Hass is currently Senior Advisor, Oncology External Innovation for Lilly Research Laboratories at Eli Lilly and Company. He leads a group responsible for harnessing external innovation through in-licensing, out-licensing, discovery collaborations, and strategic academic relationships. In this role Andrew has successfully closed multiple transactions, including a neoantigen vaccine collaboration with CureVac. Andrew joined Lilly in 2006 and has held a number of roles of increasing responsibility in marketing, new product planning, competitive intelligence, and external innovation. Andrew holds a B.S. in Molecular Biology from Michigan Technological University, an M.S. in Cell and Molecular Biology from The University of Michigan, and an M.B.A. from the Ross School of Business at The University of Michigan.

**Vida Ventures**

**Arjun Goyal**
Co-Founder & Managing Director

From 2014 through 2017, Arjun was an investment professional at 5AM Ventures, a life science focused venture firm. Arjun was a Board Observer at Aprea AB, Spyryx, Pear Therapeutics, Portal Instruments, Entrada, and Homology Medicines (NASDAQ: FIXX). At 5AM Ventures, Arjun was part of the founding team of Homology Medicines, a genetic medicines company and he also served as Acting VP of Business Development at Pear Therapeutics. Prior to joining 5AM Ventures, Arjun was Co Founder and CEO, Foresight Pharmaceuticals, a biopharmaceutical company developing hormonal treatments for infectious diseases. Arjun received his B.S. in Medical Science, Diploma in French and his M.D. degree from the Universities of Melbourne and Oxford. He completed his postgraduate medical training in Internal Medicine at the University of Sydney. He received his M.Phil. in Bioscience Enterprise from Cambridge on a Commonwealth Scholarship and his MBA from Harvard Business School. Arjun has received several awards for his work including the American Australian Association Education Fellowship, Robert Kaplan Life Science Fellowship, Oxford Clarendon Scholarship, Gates Cambridge Scholarship and Reg Waite Award for Young Australians. He is a co inventor on one patent and has served on the editorial board of an international scientific journal. Arjun is a Board Observer at Pionyr Immunotherapeutics and serves on the Committee for the American Australian Association Education Fellowship and LifeTech Advisory Board of the Swedish American Chamber of Commerce, and was on the 2016 NCI Review Committee for SBIR grants.

**Bloomberg Intelligence**

**Asthika Goonewardene**
Senior Biotech Analyst

Asthika Goonewardene is the senior biotechnology analyst with Bloomberg Intelligence, a unique research platform that provides context on industries and companies, available on the Bloomberg Professional Service at BI <GO>. Mr. Goonewardene leads coverage of the global biotech industry. Prior to this role, Mr. Goonewardene was based in Europe, covering the large cap pharmaceutical and generics sector.
Mr. Goonewardene has more than a decade of experience in research and analysis within the pharmaceuticals industry, working at firms such as Johnson & Johnson, OSI Pharmaceuticals and Piper Jaffray. Prior to joining Bloomberg in 2011, Mr. Goonewardene worked as a senior consultant at Datamonitor, advising pharmaceutical companies on lifecycle management strategies and assessing market opportunities for both blockbuster and specialty drugs.

In his roles at Bloomberg Intelligence, Mr. Goonewardene has lead a series of seminars, webinars and panel discussion on topics such as advances in immuno-oncology, deal-making, biosimilars, pricing and reimbursement, emerging market strategies, and tax inversion in the pharmaceutical sector.

Mr. Goonewardene holds a BS in Biotechnology and an MBA in Marketing, Technology Management from Rochester Institute of Technology.

**GlaxoSmithKline**

**Axel Hoos**

SVP, Therapeutic Area Head of Oncology R&D

Dr. Axel Hoos is Senior Vice President and Therapeutic Area Head, Oncology R&D at GlaxoSmithKline Pharmaceuticals (GSK). As leader of the Oncology TA he oversees both its discovery and development functions and builds the Oncology portfolio of GSK across several modalities including antibodies, small molecules, bispecific molecules and cell & gene therapies. The TA’s scientific focus is on Immuno-Oncology, Epigenetics and Cell Therapy. Dr. Hoos also serves on the Scientific Advisory Board of the HIV Cure Center, a co-venture of GSK and the University of North Carolina at Chapel Hill.

Dr. Hoos further serves as Executive Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Non-executive Director on the Board of Imugene, a biotech company, Co-Chairman of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). He further is a Scientific Advisory Group member at the Parker Institute for Cancer Immunotherapy (PICI), and Industry Co-Chair of the Partnership for Acceleration Cancer Therapies (PACT) of the U.S. Cancer Moonshot.

His efforts in Medicines Development and Global Health focus on novel and transformational therapies for life-threatening diseases, scientific and procedural innovation, and broad collaboration across multiple constituents to solve complex health problems. Through his leadership, a new paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology. Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy in Immuno-Oncology. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company.

Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.
New Enterprise Associates (NEA)

Bibhash Mukhopadhyay
Principal

Bibhash is a Principal at New Enterprise Associates (NEA), where he focuses on investing in emerging therapeutics and device companies, assisting them grow and create value. Previously, he was at AstraZeneca / MedImmune as an Associate Director of Business Development, where his responsibilities spanned end-to-end in the deal-making spectrum, from search and evaluation to transactions, with focus on the immune-oncology and immunology spaces. He started his career at Johnson and Johnson, where he held multiple Business Development roles, at different times, in Global Surgery, Oncology and Emerging Technologies. Bibhash’s doctoral research work focused on pathophysiology of retinal diseases using tools of cell biology and mathematical modeling, during which he also consulted for venture funds and start-ups.

Cowen, Inc.

Boris Peaker
Managing Director, Biotechnology Equity Research

Boris Peaker is a managing director and senior research analyst covering emerging growth biotechnology companies. Prior to rejoining Cowen in 2014, Dr. Peaker was a senior analyst at Oppenheimer & Co. and Rodman & Renshaw, covering large-, mid-, and small-cap biotechnology stocks. Dr. Peaker holds a BS in physics and chemistry from Stony Brook University and a Ph.D. in biophysics from Stanford University. He is a CFA charterholder.

Loncar Investments, LLC

Brad Loncar
Private Investor, Portfolio Manager

Brad Loncar is an independent biotech investor and analyst, and has managed a bio-tech-focused family office since 2008. Through Loncar Investments LLC, he uses his research of biotech companies and technologies to develop thematic biotech investment indexes. The Loncar Cancer Immunotherapy Index was launched in March of 2015. It is the only of its kind and consists of 30 companies leading the way in the emerging field of cancer immunotherapy. Brad previously worked at Franklin Templeton Investments and served in a Senior Advisor role at the U.S. Department of the Treasury. He is one of the most followed biotech commentators on social media and writes biotech commentary at www.LoncarBlog.com. He holds a BA in Finance from the University of Miami.

Immunicum AB

Carlos de Sousa
Chief Executive Officer

Carlos de Sousa is a medical doctor by training, having earned his degree at School of Medicine University of Lisbon and holds an Executive MBA from the Stern School of Business New York University. He has more than 25 years of senior level experience in the global pharmaceutical and biotech industry including business development, mergers & acquisitions, global marketing and clinical development. Prior to joining Immunicum he held senior positions at Nycomed/Takeda, Pfizer, Novartis, Newron Pharmaceuticals and Zealand Pharma among others.
Unum Therapeutics, Inc.

Charles Wilson
President & CEO

Charles (‘Chuck’) Wilson is Chief Executive Officer of Unum Therapeutics, a company developing a novel cellular immunotherapy platform for the treatment of cancer.

Prior to founding Unum in 2014, Chuck served as Vice President, Global Head of Strategic Alliances for the Novartis Institutes for BioMedical Research (NIBR), the research and early development division of Novartis. In this role he was responsible for leading partnering efforts to support Novartis across all disease areas up through clinical proof-of-concept. His efforts included academic and biotech collaborations, equity investing in early stage companies, in-licensing of compounds, and spin-out of assets/technologies to start ups.

Prior to joining Novartis, Chuck co-founded Archemix, a Cambridge, MA biotech company focused on the development of aptamers as therapeutics. At Archemix, Chuck served as Chief Technology Officer, responsible for both developing the company’s technology platform and managing its drug discovery efforts. As part of the senior management team, Chuck helped the company raise over $100 million in equity financing and grow to approximately 100 employees, advancing multiple programs into clinical development in the process.

Before moving into industry, Chuck was a professor in the Markey Center for the Molecular Biology of RNA at the University of California, Santa Cruz. There he determined the first x-ray crystal structures of RNA aptamers bound to their targets and developed such molecules as tools for regulating gene expression. Trained in structural biology and molecular biology, Chuck received his PhD with David Agard (UCSF, HHMI) and did his postdoctoral training with Nobelist Jack Szostak (Harvard University / Massachusetts General Hospital).

AstraZeneca

Chris Sheldon
Head of Oncology Search & Evaluation

Chris has worked in the UK at AstraZeneca (AZ) for over 15 years and is currently Head of Oncology Search & Evaluation in AZ’s Strategy team in its Oncology Business Unit (OBU). Chris and his team are responsible for scouting of new oncology technologies and leading the technical evaluation of new M&A, in-licensing, out-licensing (divestment) and collaboration opportunities in clinical stage oncology. Most recently, he led the evaluation of AstraZeneca’s recent majority $4 billion stake investment in Acerta Pharma for Calquence (acalabrutinib), as well as multiple novel immuno-oncology combination deals for AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab), including a recently announced Phase III collaboration with Incyte.

Prior to this Chris worked in early stage oncology business development and was involved in all aspects of evaluation, due diligence and negotiation of deals. Before his business development career, Chris worked in discover research at AstraZeneca as a senior research chemist. He also holds a Ph.D. in chemistry from the University of Bristol, UK and a first class honours degree from the University of Sheffield, UK.
Daiichi Sankyo, Inc.

Francis Kern
Executive Director, Oncology Search and Evaluation, Global BD

Dr. Kern is currently Executive Director of Oncology Search and Evaluation, Global Business Development at Daiichi Sankyo where he leads the U.S. group responsible for identifying and evaluating in-licensing, partnering, and external research collaboration opportunities in Oncology. In his previous position as Scientific Officer and Head of Program Development for Oncology at the Adelson Medical Research Foundation, he developed a portfolio of collaborative and interactive translational research programs in ovarian cancer, melanoma, lymphoma and lung cancer involving key opinion leaders at major academic research and Cancer Centers throughout the U.S., Europe, Australia and Israel. Prior to that, as Senior Director of Oncology at Lexicon Genetics, he implemented novel approaches to oncology drug target identification and validation and was charged with advancing targeted anticancer therapeutics. The academic portion of his career primarily involved establishing and directing a basic and translational research program on molecular and cellular mechanisms underlying breast cancer progression to antiestrogen-resistant and metastatic phenotypes. He began this program first as a Senior Staff Fellow in the Breast Cancer Section of the Medicine Branch of the National Cancer Institute and subsequently as a faculty member at the Lombardi Cancer at Georgetown University and as Director and Department Head of Biochemistry and Molecular Biology at the Southern Research Institute in Birmingham, Alabama where he also held the Adolph Weil Endowed Chair in Cancer Biology. While there, he also had program and executive oversight leadership roles within the University of Alabama at Birmingham’s NIH-Designated Comprehensive Cancer Center as co-leader of their Women’s Cancer Program. He has extensive experience on federal, state and foundation review panels evaluating oncology-focused basic, translational and small business research grant applications. He received his bachelor’s degree in Biological Sciences from Rutgers College and his Ph.D. in Microbiology from Rutgers University and his postdoctoral training in Cellular and Molecular Biology at the NYU Medical Center.

Immunovaccine, Inc.

Frederic Ors
Chief Executive Officer

Fred has served as our Chief Executive Officer since April 2016. As CEO, he has led the transformation of IMV into a leading clinical-stage immune oncology company with world-class collaborators and a strong scientific foundation. He has more than 20 years of experience in the biopharmaceutical industry, having served in a number of management roles encompassing business development, intellectual property, strategic planning, pre-marketing and communication. Before joining IMV, Fred spent 14 years at Medicago serving in many roles of increasing responsibility, most recently as Vice President of Business Development and Strategic Planning. He had been an integral part of Medicago’s success, including securing more than $300M CAN in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts, and the $357M CAN deal acquisition by Mitsubishi Pharma in 2013. Fred served as second Vice-Chair of the Vaccine Industry Committee of Biotech Canada between 2012 and 2016. Prior to Medicago, he was licensing manager at the University Paris VII-Denis Diderot, one of the largest science and medical University in France. He has a BSc degree in Biology and a Master degree in Management from the University of Angers (France).
Gary Sclar is the Vice President, Dana-Farber Innovation at the Dana-Farber Cancer Institute. He leads all aspects of business development, deal structure, negotiation and closing of strategic alliances and partnerships for the Dana-Farber Cancer Institute. Before joining the Dana-Farber, Gary held the position of Chief Strategy Officer for MedMetrics Health Partners and Public Sector Partners. Gary has over 18 years of technology licensing experience, having worked in the technology licensing offices of Northeastern University, Brigham and Women's Hospital, and the University of Massachusetts Medical School. Prior, Gary directed laboratories at Washington University School of Medicine and The Jackson Laboratory, specializing in nuclear transplantation and the generation of transgenic and embryonic stem cell knock-out animals. Gary has a Bachelor of Science degree from the University of Massachusetts, a Master's degree from Webster University School of Business, and a JD degree from Massachusetts School of Law. He is admitted to the Massachusetts Bar and United States District Court in Massachusetts.

Dr. Frost has been Managing Director of F1 BioVentures, LLC since 2015. Previously, he led the Health Sector of Intrexon Corporation, a multinational public biotechnology company, where he was responsible for expanding their oncology franchise and gene and cellular-based therapies for a number of orphan diseases. From 1999 to 2014, Dr. Frost was at Halozyme Therapeutics, a San Diego public biotechnology company he co-founded, focused on oncology biologics and medication delivery, where he served on the Board of Directors and in numerous operational roles, including Chief Scientific Officer since 2002, and CEO since 2010. He has authored multiple scientific peer-reviewed and invited articles, and is an inventor on key patents supporting a number of FDA approved biologics. Dr. Frost is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and is registered to practice before the U.S. Patent and Trademark Office. Dr. Frost earned his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, his Ph.D. in the Department of Pathology at the University of California, San Francisco and postdoctoral research at the Sidney Kimmel Cancer Center. As an entrepreneur, Dr. Frost brought the founding platform technologies to Halozyme and secured the initial capital for the company. In 2012, Gregory Frost was named by Forbes as one of America's 20 most powerful CEO's 40 and under, and was a finalist for Ernst and Young's Entrepreneur of the Year in San Diego. Dr. Frost additionally serves on the Board of directors of BioCom, a member-driven organization serving life science community of Southern California and BioAtla.
BeiGene Ltd.

Guillaume Vignon
Senior Vice President Business Development

Guillaume Vignon is Senior Vice President Business Development at BeiGene, responsible for leading all business development activities, from search & evaluation of partnering opportunities across several therapeutic areas, and all the way through till deal closing.

Guillaume was previously Vice President, Global Head Oncology and Immuno-Oncology Licensing & Business Development at Merck KGaA / EMD Serono. Throughout his career, Guillaume led the closing of complex transactions and forged several strategic partnerships in the fields of Immuno-Oncology, Oncology, Companion Diagnostic, and Antibody Discovery.

Guillaume holds a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6 / Institut Pasteur, and an MBA from Hult International Business School, Cambridge, MA.

Adaptimmune Ltd.

Helen Tayton-Martin
Chief Business Officer

Dr. Helen Tayton-Martin has over 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008.

Dr. Tayton-Martin transitioned to become Adaptimmune’s Chief Business Officer in March 2017, having served as its Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from 5 to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its NASDAQ IPO.

Today, she is responsible for optimizing the strategic and commercial opportunity for Adaptimmune’s assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company’s strategic partnership with GSK.

Dr. Tayton-Martin also serves as a non-executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.

Fred Hutchinson Cancer Research Center

Hilary Hehman
Director of Strategic Partnerships & Alliances

Hilary Hehman is the Director of Strategic Partnerships and Alliances at Fred Hutch, where she manages strategies aimed at growing the institutional portfolio of strategic partners working with Hutch researchers to achieve the Center’s mission – curing cancer. Having started her career as a scientist working in the Developmental Chemotherapeutics and Experimental Immunology Divisions at the National Cancer Institute, Hilary is able utilize her understanding of cancer biology to create partnerships that accelerate translation of academic science through collaboration with industry. Hilary previously held a similar role at Cincinnati Children’s Hospital Medical Center, and was formerly a research and policy analyst at the Judicial Council of California. Hilary holds a B.S. in Microbiology from Miami University of Ohio, an M.S. in Entrepreneurial Biotechnology from Georgetown University, and a J.D. from the University of California-Hastings College of the Law.
**Hookipa Biotech AG**

**Igor Matushansky**  
CMO, Global Head Research and Development

He joins Hookipa from Daiichi Sankyo, where he was the Global Head of Translational Development for Oncology. He led Daiichi Sankyo’s international research unit focused on early oncology therapeutic programs, strategy and development, and was accountable for development activities from post-target identification basic science research to first-in-man trials and proof-of-clinical concept. Prior to that, Dr. Matushansky was at Novartis where he was Global Head for Clinical and Scientific Development at its Gene & Cell Therapy Unit as well as a Global Clinical Program Lead within Novartis’ Oncology Translational Medicine Unit. Before being recruited to the pharmaceutical industry, Dr. Matushansky was a Professor at the Columbia University Medical Center where he ran an independent laboratory and clinic focusing on the molecular biology, translational opportunities and clinical trials in sarcomas. Currently he is an Adjunct Professor of Medical Oncology, Columbia University. He grew up in New York City where he received his undergraduate B.A. degree, summa cum laude, from Columbia University. He then went on to attend the Albert Einstein College of Medicine where he received his MD as well as a PhD in Molecular Biology. He performed his Internal Medicine residency at New York Presbyterian Hospital – Weill Cornell Medical Center and then completed a fellowship in Medical Oncology as well as a post-doctoral research fellowship in Cancer Biology at the Memorial Sloan Kettering Cancer Center.

---

**Defined Health, a Cello Health business**

**Jeffrey Bockman**  
EVP, Oncology Practice Head

Jeff leads the Oncology Practice at Defined Health. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments, along with strategic analyses about future trends, during his tenure at DH. He often speaks at conferences on scientific/clinical and commercial/strategic issues in cancer, especially in Immuno-Oncology.

Before joining Defined Health, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions, and holds four patents in the use of ribozymes.

He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.

Jeff is a member of the Licensing Executives Society (LES), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the American Society of Gene and Cell Therapy (ASGCT).
**BeiGene Ltd.**

**JI LI**  
EVP, Global Head of Business Development

Dr. Ji Li has more than 20 years of business development and R&D experience in the biopharmaceutical industry. He is currently Executive VP and Global Head of Business Development at BeiGene where he oversees the company’s partnering activities worldwide, including leading the recently completed landmark strategic transaction with Celgene. Prior to BeiGene, Dr. Li served as VP of Business Development and Licensing at Merck, where he led the group that was responsible for BD activities of all late-stage inbound and outbound opportunities globally. Prior to Merck, Dr. Li was Executive Licensing Director, External R&D at Amgen where he led the company’s product search and evaluation BD team. Earlier in his career, Dr. Li was key member of the Amgen research team discovered and validated the RANKL signaling pathway that has led to the successful development and commercialization of Deno-sumab. Dr. Li obtained his B.S. in Pharmacology from Shanghai Medical University and Ph.D. in Neuro-science from Mount Sinai School of Medicine in New York.

**F-star Biotechnology Ltd.**

**John Haurum**  
Chief Executive Officer

John has over 15 years’ experience in building and leading biotech companies across discovery, development, financing and business development. He successfully managed several monoclonal, oligoclonal, and bispecific antibody products into clinical development, as well as managed and developed numerous collaborations with biopharmaceutical companies in the US, Europe, and Japan. Prior to joining F-star, John was VP Research, Biologics Products at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. Previously, he was a cofounder and Chief Scientific Officer of Symphogen A/S, a Danish biotechnology company developing therapeutic antibody combinations. John holds an MD from University of Aarhus, Denmark and a D.Phil, in Immunology from the Institute of Molecular Medicine, University of Oxford, UK.

**Pfizer, Inc.**

**John DeYoung**  
Vice President, Oncology Business Development

John is Vice President of Worldwide Business Development for Pfizer Oncology. He is a member of the Oncology Leadership Team and the Worldwide Business Development Leadership Team. John joined Pfizer in 1991 and has held leadership positions in Finance, Marketing, Commercial Development, and Business Development. John received a bachelor’s degree in Business from Michigan State University in 1985 and an MBA from the University of Chicago in 1990.
Jonathan Kfoury is a Managing Director and Partner in L.E.K. Consulting’s San Francisco office, focused on biopharmaceuticals, medical technology and life sciences. He joined the firm in 2006, and since that time has led an extensive set of engagements with global biopharmaceutical, medical technology and diagnostic clients across human health, animal health and agribusiness markets. Jonathan advises clients on commercial strategy and life-cycle management for in-line products, market access and commercialization planning for pipeline assets, and growth / partnering strategy. With an operating background in both Clinical and Business Development at specialty biopharmaceutical companies, Jonathan brings a hands-on understanding of internal decision-making needs to his advisory work with clients.

In addition to significant experience in immunology, oncology, men’s/women’s health and CNS/pain management, Jonathan’s interests include growth strategy for antibiotics and infectious-diseases, biosimilars and digital health opportunities.

Jonathan has published and spoken extensively across the industry on the crisis of antimicrobial resistance, barriers to investment into novel antibiotics, public/private partnership, and key opportunities for pharmaceutical, vaccine, and diagnostic manufacturers within anti-infectives more broadly.

Prior to joining L.E.K., Jonathan was a Business Development executive for Acusphere and Purdue Pharma, and manager of global Clinical Development for Cubist Pharmaceuticals’ (now Merck) blockbuster antibiotic Cubicin® - the most successful IV antibiotic launched in US history. In addition to global management training at INSEAD, Jonathan earned an S.M. in Health Policy & Management from Harvard University, and graduated from Trinity College with a Bachelor of Science degree in Neuroscience.

Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology. Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years. While at Pfizer, she built and led immuno-oncology teams, was a member of the Vaccine Immunotherapeutics leadership team and served as the head of the Immunopharmacology team. Her duties included overseeing the assessment of all cancer vaccine in-licensing opportunities, and developing and launching Pfizer’s first clinical cancer vaccine program deploying a variety of vaccine platforms and immune modulators to build a multi-component vaccine-based immunotherapy regimen. Prior to joining Pfizer, Jooss served as vice president of Research at Cell Genesys, Inc. where she oversaw all research activities related to the company’s cancer vaccine and oncolytic virotherapy programs. Dr. Jooss received her Ph.D. in Molecular Biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania. She is on the editorial board of Molecular Therapy and Journal of Gene Medicine and is a member of the immunology and educational committee for the American Society of Gene Therapy as well as the Industry Task Force of the Society for Immunotherapy of Cancer (SITC).
The Leukemia & Lymphoma Society (LLS)

Lee Greenberger
Chief Scientific Officer

Since September 2013, Dr. Lee Greenberger has been the Chief Scientific Officer of the Leukemia and Lymphoma Society (LLS). His responsibilities focus on planning and executing the strategy for all LLS research programs. This effort includes a grant portfolio with over 230 active projects worldwide, and the Therapy Acceleration Program, a venture philanthropy initiative, with over 15 assets. Dr. Greenberger guides LLS’s mission to translate innovative research that ultimately will pave the way for new therapies to treat blood cancers. The total annual budget for these activities is approximately $50 M.

Immediately prior to LLS, Dr. Greenberger was global head of search and diligence for oncology and immunology at Bristol-Myers Squibb. Prior to that, he served for six years as vice president for research at Enzon Pharmaceuticals and over 15 years at Johnson & Johnson and Wyeth Pharmaceuticals (now Pfizer), where he advanced over 10 new oncology therapeutics into the clinic. He was given the President’s Award for his work at Wyeth.

Dr. Greenberger holds a BA from the University of Rochester and a Ph.D. from Emory University. He has done post-doctoral work at Columbia University and the Albert Einstein College of Medicine. Dr. Greenberger has produced more than 85 publications, mostly focused on oncology, during his research career.

Nektar Therapeutics

Lisa Decker
Vice President, Business Development

Lisa Decker leads Business Development for Nektar and is responsible for partnering activities and strategy. Since joining Nektar in 2008, Dr. Decker has held positions of increasing importance throughout the organization including program and alliance management, business strategy and operations, and business development. Dr. Decker led negotiations, numerous collaborations for NKTR-214 with partners such as Takeda, Syndax and others, including the landmark strategic collaboration agreement with Bristol-Myers Squibb and the co-development/co-promotion agreement with Eli Lilly & Co for NKTR-358.

Prior to joining Nektar, Dr. Decker was Associate Director of Technology Licensing at the University of Massachusetts Medical School where she lead the partnering and intellectual property strategy efforts for a diverse array of early stage technologies. Dr. Decker holds a Ph.D. in Immunology from Tufts University School of Medicine and conducted her postdoctoral training at Harvard Medical School.
Loïc Vincent
Head Oncology & Immunology Research Partnerships

Oncology Scientist with international academia/biotech/pharma industry experience, Loïc is a Pharmacologist by initial training with a PhD received in 2003 from the University of Rouen, France. During his thesis, Loïc worked in collaboration with Bayer Pharma and received the Young Scientist Award from the Bettencourt-Schueller’s Foundation for his work. Loïc did a post-doctoral fellowship in Oncology at Weill Medical College of Cornell University in NY, where he worked in collaboration with ImClone Systems & OxiGene. Loïc was then appointed Head of Pharmacology at Endotis Pharma before joining Sanofi as Head of Pharmacology for Sanofi Oncology business unit in 2009. In 2013, Loïc was given the responsibility to build & lead the Immunotherapy Strategy & Execution Team dedicated to shape and implement a strategy for Sanofi to enter the field of immunotherapy, and was then appointed Head of Oncology External Innovation.

Loïc joined Takeda in 2016 and is global Head of Oncology & Immunology Research Partnerships.

Loïc is author and co-author of 33 scientific papers and 45 poster/oral presentations.

Luke Li
Partner & Managing Director

Dr. Luke Li has 30+ years of experience in the US healthcare industry, particularly in the biopharmaceuticals business, from drug discovery to product and clinical development to M&A/business development. Currently Dr. Li is a Managing Director and Partner at Ally Bridge Group (“ABG”), a global healthcare investment group, where he leads and formulates global biopharma investment strategy as well as leading scientific due diligence, evaluation and deal execution. He also serves as a senior advisor to several of ABG’s biotech portfolio companies, including Senior VP, Head of Business Development and a Board Member of Cold Genesys, a phase III immune-oncology company based in the US.

Before joining ABG, Dr. Li was the Global Head of Bio-innovation at Pfizer R&D based in Boston for more than 5 years, where he led the research, evaluation and business development, including M&A, in-licensing, of many of the world’s cutting-edge novel biotechnologies. One of his primary focus has been on cancer immunotherapy. Trained as a medical doctor in Hematology and Oncology, Dr. Li was actively involved in Pfizer’s global R&D transactions, such as strategic partnerships on I-O and biotherapeutic technologies, etc.

Before joining Pfizer, Dr. Li was an Executive Director at Amgen for nearly 18 years, playing important roles in biologic drug discovery and product as well as clinical development, where he oversaw the biologics discovery department and advanced more than 3 dozen biologics into clinics, including 4 marketed products. Prior joining Amgen, Dr. Li was an Assistant Professor in Medicine at Washington University Medical School in St Louis after completing his fellowship training in Hematology/Oncology. He was a recipient of NIH Clinical Investigator Awards and obtained his MD from China Fujian Medical University with postgraduate study in Pharmacology.
eTheRNA immunotherapies NV

Marc Dechamps
Acting Chief Executive Officer

Marc Dechamps is a biologist with an extensive experience in the Pharmaceutical industry in international and local business positions. He started his career by holding several sales and marketing positions at Glaxo, GW and GSK. His last position at GSK Pharmaceuticals Belgium was Executive Director of the Commercial department « Specialty care & Vaccines ». End 2009 he became Head of the European Mid-Size Countries Region at ViivHealthcare, a spin out company created by GSK and Pfizer. In parallel he built and managed a European Commercial - Market Access Operations team dedicated to the launch of the new assets of ViivHealthcare. Before joining eTheRNA as Acting CEO Marc was Managing Director of Delphi Genetics, a Belgian Biotech company specialised in the production of plasmid DNA.

Oppenheimer & Co., Inc.

Mark Breidenbach
Executive Director and Senior Analyst, Biotechnology

Mark Breidenbach is an Executive Director and Senior Analyst covering Emerging Biotechnology. Before joining Oppenheimer, Mark was most recently a lead analyst covering Biotechnology at Roth Capital Partners. Prior to his Wall Street career, Mark served as a scientist at Nature Publishing Group, and as a specialist in glycoproteomics and metabolic engineering in the Department of Chemistry at the University of California Berkeley. Mark holds a Ph.D. in Molecular and Cellular Physiology from Stanford University, a M. Phil. from the Department of Molecular Biophysics and Biochemistry at Yale University, and a dual B.A. in Biology and Chemistry from Cornell University.

Merck KGaA

Matthias Müllenbeck
Director Global Oncology Licensing and Business Development

Dr. Matthias Müllenbeck is Director Global Licensing & Business Development at Merck Biopharma, responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology. Throughout his career at Merck, Matthias concluded successfully negotiations on various strategic partnerships for asset-, technology-, and diagnostic-licensing deals. Matthias holds a PhD in immunology from the Humboldt-University of Berlin. He worked during this time as a scientific project leader at the Max-Planck Institute for Infectionbiology Berlin, Germany, and the Albert-Schweitzer Hospital in Lambaréné, Gabon. He is married and lives in Frankfurt.
Genocea Biosciences, Inc.

Pamela Carroll
SVP, Immuno-Oncology

Pamela Carroll, Ph.D. joined Genocea in 2016 to lead the company’s immuno-oncology efforts. She brings expertise in cancer biology and immuno-oncology to the development and strategic direction of Genocea’s programs. Her previous positions include vice president of oncology discovery at Roche Pharma Research and Early Development, vice president of Janssen oncology at Johnson and Johnson Innovation, and founding Head of Research at the Belfer Institute for Applied Cancer Science at Dana Farber Cancer Institute. Dr. Carroll developed her drug discovery experience at Bristol-Myers Squibb in applied genomics and Merck Research Laboratories in oncology. Dr. Carroll earned her B.A. in biology at St. Michael’s College in Vermont, a doctorate in cellular biology at Stony Brook University, and a post-doctorate fellowship at Stanford University.

Opplenheimer & Co., Inc.

Michael Margolis
Co-Head of Healthcare Investment Banking

Michael Margolis is Co-Head of Healthcare Investment Banking at Oppenheimer & Co. Inc., and has over two decades of Investment Banking experience in the Life Science sectors. Most recently, Margolis served as Head of Healthcare Investment Banking at ROTH Capital Partners, where he executed more than 300 financing and strategic advisory transactions and raised in excess of $12.5 billion. He previously held a number of key positions in the financial services and pharmaceutical industries, including roles at Novartis Pharmaceuticals and Eli Lilly. Margolis received his MBA in Finance from New York University, Stern School of Business, and is a registered pharmacist from Rutgers University, College of Pharmacy.

Vybyl Biopharma

Nathan Gianneschi
Founder

Nathan C. Gianneschi received his B.Sc(Hons) at the University of Adelaide, Australia in 1999. In 2005 he completed his Ph.D at Northwestern University. Following a Dow Chemical postdoctoral fellowship at The Scripps Research Institute, in 2008 he began his independent career at the University of California, San Diego where, until June 2017, he was Teddy Taylor Scholar and Professor of Chemistry & Biochemistry, Nano-Engineering and Materials Science & Engineering. In July of 2017, Gianneschi accepted a position at Northwestern University where he is currently Jacob & Rosaline Cohn Professor of Chemistry, Materials Science & Engineering, and Biomedical Engineering. The Gianneschi group takes an interdisciplinary approach to nanomaterials research with a focus on multifunctional materials with interests that include biomedical applications, programmed interactions with biomolecules and cells, and basic research into nanoscale materials design, synthesis and characterization. For this work he has been awarded the NIH Director’s New Innovator Award, the NIH Director’s Transformative Research Award and the White House’s highest honor for young scientists and engineers with a Presidential Early Career Award for Scientists and Engineers. Prof. Gianneschi was awarded a Dreyfus Foundation Fellowship, is a Kavli Fellow of the National Academy of Sciences, a Fellow of the Royal Society of Chemistry, and is an Alfred P. Sloan Foundation Fellow. In 2018, Gianneschi founded Vybyl Biopharma, a start-up company focused on the development and commercialization of metabolite-armed drug technologies spun out of UC San Diego.
TapImmune, Inc.

Peter Hoang
President & CEO

Mr. Hoang brings over twenty years of investment banking, venture capital, immunooncology and public company executive management experience to TapImmune, serving most recently as Senior Vice President of Business Development and Strategy at Bellicum Pharmaceuticals. Previously, as the Managing Director of Innovations at The University of Texas MD Anderson Cancer Center, he headed the new venture formation and development effort for the institution. Before joining MD Anderson, Mr. Hoang was a senior investment banker, most recently as Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group. He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. He earned an M.B.A. with high honors distinction from the Anderson School of Management at UCLA and a B.A. from Yale University.

OrbiMed Advisors, LLC

Peter Thompson
Private Equity Partner

Peter Thompson, M.D., is currently a Private Equity Partner with OrbiMed who brings over 25 years of industry experience. He held executive positions at Becton-Dickinson and Chiron, co-founded and was CEO of Trubion Pharmaceuticals (NASDAQ: TRBN), co-founded Corvus Pharmaceuticals (NASDAQ: CRVS), Cleave Biosciences, Silverback Therapeutics and serves as a director on several company boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

H.C. Wainwright & Co., LLC

Raghuram Selvaraju
Managing Director, Senior Healthcare Analyst

Dr. Raghuram Selvaraju, also known as Ram, Ph.D., MBA has served a Managing Director of Equity Research and Senior Healthcare Analyst at H.C. Wainwright & Co, LLC, since August 2015. Prior to this, he served as a Managing Director and Senior Healthcare Analyst at MLV & Co. Earlier, Dr. Selvaraju served as Managing Director, Head of Healthcare Equity Research and Senior Analyst at Aegis Capital Corp. since March 2012. Before that, he served as a Senior Vice President in Equity Research and Senior Biotechnology Analyst at Morgan Joseph TriArtisan since May 2011. From 2010 to March 2011, Dr. Selvaraju served as a Senior Equity Research Analyst covering the biotechnology and pharmaceuticals sectors at NOBLE Capital Markets. From 2009 to 2010, he served as the Senior Vice President and Head of Healthcare Equity Research at Hapoalim Securities USA, Inc., covering biotechnology, specialty pharmaceuticals, molecular analytics and diagnostics. Between 2005 and 2008, Dr. Selvaraju worked in biotechnology equity research at Rodman & Renshaw. He has over a decade’s worth of experience in equity research and is considered one of the most prolific equity research analysts covering the healthcare sector. Prior to entering equity research, Dr. Selvaraju started his career at the Serono Pharmaceutical Research Institute in 2000. He served as a Technician and Pharmaceutical Researcher at the firm until 2004. Dr. Selvaraju designed models and user interfaces for analysis of gene expression data from quantitative real-time RT-PCR; led multi-disciplinary teams developing animal models to identify novel therapeutic products; and discovered the company's first novel protein candidate. He has nearly two decades' worth of total experience in the biotechnology and pharmaceutical sectors.
Robert Radinsky, Ph.D. is Vice President, Oncology Scientific Innovation at Janssen Research & Development, LLC. He represents the Oncology Therapeutic Area in Johnson & Johnson Innovation, Boston. In this role, he is responsible for identifying and fostering innovation that supports the Oncology Therapeutic Area strategies.

Prior to this role, he was Vice President, Discovery Research for the Oncology Therapeutic Area at Janssen Research & Development, LLC. In this role, he was responsible for leading Janssen's research efforts to drive the development of a robust and sustainable oncology drug discovery pipeline aligned with our Disease Area Stronghold strategies. Bob has had a very successful oncology research career in both academics and industry. Prior to joining Janssen, he was Executive Director, Oncology Research at Amgen Inc., where he led groups at multiple research sites including Thousand Oaks, California, and Cambridge, Massachusetts. He was responsible, in part, for research and/or pharmacology for numerous active targeted therapeutic anti-cancer programs (protein, small molecule and nanotechnology modalities), culminating with multiple candidates in clinical trials and an approved drug for the treatment of colorectal carcinoma.

Before joining the industry 16 years ago, Bob was on the faculty at The University of Texas MD Anderson Cancer Center, first serving as an American Cancer Society Postdoctoral Research Fellow in the Department of Cell Biology, and eventually becoming a tenured Associate Professor in The Department of Cancer Biology. He continued as an Adjunct Professor at MD Anderson after joining industry.

Bob has published more than 140 peer-reviewed articles, holds multiple patents, and is a present/past member of numerous societies, including the American Association for Cancer Research, Board of Directors for the Metastasis Research Society, the American Association for the Advancement of Science, and the Scientific Advisory Board, The Aspen Cancer Conference. He is an Editorial Member and/or Ad Hoc reviewer for more than 20 scientific journals and has served on review panels for a number of granting agencies, including National Institutes of Health/National Cancer Institute, Department of Defense Prostate and Breast Cancer Research Programs, and the Veterans Administration Merit Review Board.

Bob earned his doctorate in Molecular Biology and Microbiology from Case Western Reserve University School of Medicine in Cleveland, Ohio.
Roche Innovation Centre

**Robert Silverman**
Personalized Healthcare (PHC) Business Strategy & Partnering

Since Jan 2018 Bob's is in a newly established role at Roche, in the Diagnostics division with dual responsibilities at both a divisional and business area level. From 2013 until his current role Bob Silverman led the “External Drug Discovery Partnering” team of Roche Partnering. Among other matters, Bob was responsible for delivering a structured and systematic approach to venture capital that translated to reach into drug discovery stage innovation via deals originating from venture capital interactions. Prior, from 2010 - 2012, Bob was a project leader for Merger & Acquisitions, in the Strategic Partnering Group of Roche Partnering. From 2003 – 2010 Bob was a Global Licensing Director for Roche Pharma Partnering, responsible for negotiating intellectual property based licensing agreements across the full value chain of the Pharma business, ranging from enabling technologies and early phase opportunities to clinical stage assets to promoting and divesting marketed products. From 2001 – 2003 Bob was a Global Licensing Attorney. Bob joined Roche in 1993. Early in his career at Roche Bob was Senior Counsel for the US Affiliate patent department. Bob holds a degree in Chemistry from Franklin & Marshall College and a J.D. from Boston University School of Law, and is a registered patent attorney.

Selecta Biosciences, Inc.

**Takashi Kei Kishimoto**
Chief Scientific Officer

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Caribou Biosciences, Inc.

**Timothy Herpin**
Chief Business Officer

Timothy Herpin Ph.D., is CBO of Caribou Biosciences where he leads the company’s efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities. Prior to Caribou, Tim was Vice President, Head of Transactions at AstraZeneca and led a group of business development professionals involved in all aspects of transactions negotiation and execution. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for Neuroscience and subsequently for Oncology. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmaceopia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.
Daiichi Sankyo, Inc.

William Kuziel
Oncology Search and Evaluation, Global Business Development

Dr. Kuziel joined Daiichi Sankyo in 2008 and is currently Director in the Search and Evaluation Group, BD&L. He is responsible for identifying and evaluating opportunities for research collaboration, in licensing and M&A in the areas of antibody-drug conjugates, immuno-oncology, cell therapy and advanced technology platforms.

Dr. Kuziel received his B.S. in Biology from the Pennsylvania State University and his Ph.D. in Immunology from the University of Texas Southwestern Medical Center at Dallas. He did post-doctoral training in Immunology at the Howard Hughes Medical Institute at the Duke University Medical Center.

After two years as a visiting scientist at the University of North Carolina Medical Center at Chapel Hill, Dr. Kuziel joined the faculty of the Department of Molecular Genetics and Microbiology at the University of Texas at Austin as an Assistant Professor. His research focused on making and using novel knockout mouse strains to study the molecular and cellular basis of inflammatory disease processes. He also designed and taught an undergraduate course in Immunology and Infectious Disease. In his research career he has published 120 peer-reviewed scientific articles.

Dr. Kuziel began his career in drug development in 2004 at Protein Design Labs where he established and led a research group to validate novel therapeutic targets and test monoclonal antibody drug candidates in a variety of inflammatory disease models. He also served on several clinical development and life cycle management teams.

Cleveland Clinic

Yogen Saunthararajah
Professor of Medicine, Staff Physician and Co-Leader of the Developmental Therapeutics Program

Yogen Saunthararajah is a Professor of Medicine, Staff Physician and Co-Leader of the Developmental Therapeutics Program at the Taussig Cancer Institute of Cleveland Clinic and Case Comprehensive Cancer Center in Cleveland, and founding-scientist of EpiDestiny. His research and drug development efforts focus on a fundamental and common distinction between normal and malignant self-replication, that enables non-cytotoxic inhibition of specific corepressors to selectively terminate malignant self-replication independent of the frequently non-functional p53-system (cell suicide program) in cancer cells. The same treatments can moreover trigger immune-recognition of cancers (convert tumors from ‘cold’ to ‘hot’) while sparing immune-effectors, and are therefore a rational platform for increasing the spectrum of responses to immune checkpoint blockade. An important co-focus of the Saunthararajah group is non-cytotoxic epigenetic induction of fetal hemoglobin, for sustainable, life-long disease modification of the beta-hemoglobinopathies.
Bohe Angel Fund

Yuwen Liu
Founding Partner & CEO

Founding Partner of BOHE Angel Fund, a 200M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI, etc. This is the first angel fund focusing on healthcare technology-driven start-ups in China, with Xiaodong Wang and Yigong Shi sitting on its scientific advisory board. It has invested into XinKangHe biological, Transcriptic, SmartNuclide, Athelas Therapeutics, CoolLing Biotech, and HighField BioPharmaceutical covering drug discovery, diagnostic and innovative service solutions.

Before she sets up this fund, she was Chairwoman & CEO then executive director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) for 9 years, when she was also Investment Committee Member for BioVENTURE Fund, and Board Director of Innovent, Admera Health, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies.

She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager. In 2003, she joined Perrigo as first Chief Representative to set up its China operation.

She graduated from China Pharmaceutical University with master degree in Pharmaceuticals and Master of Management at Fudan University and Norwegian Management School BI. She is a licensed pharmacist.
ACM Biolabs Pte Ltd.

COMPANY PROFILE

ACM Biolabs’ proprietary polymersome technology allows highly targeted delivery of antigens to antigen-presenting cells in order to elicit a very strong antigen-specific immune response. We are partnering with leading neoantigen companies to enhance the response to their peptides or proteins and are working on DNA and RNA delivery in parallel.

While our human vaccines are at a preclinical phase, our technology is currently being scale up and taken through regulatory approval for a lead veterinary vaccine candidate by our subsidiary, AAVACC Pte Ltd. ACM Biolabs is leveraging off the extensive safety testing and scale up work conducted for the veterinary vaccines in order to accelerate our path to the clinic for oncology vaccines.

MANAGEMENT TEAM

- Dr. Madhavan Nallani - Founder & CEO
- Dr. Peter Moran - COO
- Dr. Erich Erber - Director

PIPELINE

We are developing vaccines against a few selected targets. These targets are within the areas of infectious disease and oncology. Our targets are currently confidential, however, we intend to make them public as soon as practical, and so we encourage you to contact us or revisit our site to see what these are.
eTheRNA immunotherapies NV

COMPANY PROFILE

eTheRNA immunotherapies’ mission is to help patients to overcome a broad range of cancers by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now. The Trimix platform could be directly injected to the patients alone or in combination with tumor-specific antigen mRNA.

MANAGEMENT TEAM

- Marc Dechamps - Acting CEO
- Sonja Van Meirvenne - QC & Regulatory Affairs Lead
- Dirk Van Broekhoven - General Counsel and HR Lead
- Marina Cools - Clinical Lead
- Luc Lammens - Finance Lead
- Bernard Sagaert - QA Lead
- Marnix Collier - Head of Manufacturing
- Peter Tomme - Preclinical Lead

PIPELINE

eTheRNA aims to provide preclinical and clinical proof of evidence to support the further development of the TriMix technology into an injectable in vivo product, that can be made available “off-the-shelf”.

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adjuvant melanoma:</strong> Intraocular EC1-006 immunoread-out PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Metastatic melanoma:</strong> Intraocular EC1-006 plus CPI immunoread-out clinical effect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TNBC:</strong> Intraocular EC1-007 immunoread-out tumor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TriMix (EC1-001)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer: Intraocular TriMix before surgery or neo-adjuvant therapy Immune read-out tumor (Collaboration with VUB)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV patients on antiretroviral therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Horizon 2020 project) Intranasal HIVARNA or personalized RNA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- E011-MEL, n = 10 low dose n = 10 at high dose
- E011-MEL amendment n = 15 (IN) + n = 5 (IT)
- VUB study n = 12 (placebo), 3 times n = 8 (3 concentrations TriMix)
- INIARNA
- HIVACAR

ADDRESS
Galileilaan 19
Niel, 2845
Belgium

WEBSITE
www.etherna.be

E-MAIL
info@etherna.be

PHONE
+32 3 369 17 40

COMPANY TYPE
Private

SECTOR
Immunology, Immunotherapies

FOUNDED
2013
F-star Biotechnology Ltd.

**COMPANY PROFILE**

F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients. Through our highly efficient Modular Antibody Technology™ platform, we are building and progressing an extensive immuno-oncology pipeline of mAb²™, a novel class of disruptive bispecific antibodies designed to unlock new biology which cannot be achieved by combining monospecific drugs. F-star’s technological expertise and scientific approach have been validated through strategic partnerships with leaders in the pharma and biotech industries.

Find out more at www.f-star.com. Connect with us via LinkedIn and Twitter.

**MANAGEMENT TEAM**

- John Haurum - Chief Executive Officer
- Jane Dancer - Chief Business Officer
- Tolga Hassan - Chief Financial Officer
- Neil Brewis - Chief Scientific Officer
- Mihriban Tuna - Vice President, Drug Discovery
- Mike Davies - Vice President, Protein Science
- Michelle Morrow - Vice President, Preclinical Translational Pharmacology
- Alison McGhee - Vice President, Intellectual Property

**PIPELINE**

F-star is developing a pipeline of bispecific antibodies focused on oncology and immuno-oncology.

<table>
<thead>
<tr>
<th>DISCOVERY</th>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>FS20</td>
<td>FS29</td>
<td>FS320</td>
</tr>
<tr>
<td>FS22</td>
<td>FS31</td>
<td>FS322</td>
</tr>
</tbody>
</table>

- **Fcab building blocks**
  - Highly efficacious Fcab for the generation of first-in-class mAb² in immuno-oncology
- **mAb² candidates**
  - First-in-class bispecific antibodies in immuno-oncology
- **mAb² lead candidates**
  - First-in-class bispecific antibodies in immuno-oncology

First-in-class bispecific antibody in immuno-oncology targeting two checkpoint inhibitors: LAG-3 and PD-L1

Potential to deliver greater efficacy with better tolerability in a wide range of tumors.
Genocea Biosciences, Inc.

**COMPANY PROFILE**

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive algorithms to find target antigens, we have been able to successfully develop ATLAS, our proprietary, high-throughput technology platform, to identify target antigens of T cells based on actual human immune responses. We are focused on using ATLAS’s superiority in neoantigen identification to develop neoantigen cancer vaccines.

GEN-009 is our most advanced neoantigen vaccine candidate for which we expect to initiate a Phase 1 clinical trial in the second half of 2018. GEN-009 is an adjuvanted neoantigen peptide vaccine that is designed to direct a patient’s immune system to attack their tumor. GEN-009’s neoantigen peptides are identified using ATLAS, which recalls a patient’s pre-existing CD4+ and CD8+ T cell immune responses.

While we focus on advancing GEN-009 into the clinic and exploring next generation vaccine technologies, we are also actively seeking to partner certain applications of our ATLAS platform. Programs available for partnership include:

- **Antigen Discovery**: The versatility of our ATLAS platform not only allows the identification of neoantigens, but also tumor-associated antigens, viral-associated antigens, and T cell receptors.
- **Immune Response Profiling**: ATLAS can also be used as a blood-based, non-invasive assay to detect differing immune responses in patients successfully and unsuccessfully treated with cancer therapies to inform patient selection in clinical trials and clinical practice.

**MANAGEMENT TEAM**

- Pamela Carroll, Ph.D. - SVP, Immuno-oncology
- Chip Clark - President and Chief Executive Officer
- Jessica Baker Flechtner Ph.D. - Chief Scientific Officer
- Eric S. Hoffman - Chief Business Officer
- Narinder Singh - SVP, Pharmaceutical Sciences and Manufacturing

**PIPELINE**

<table>
<thead>
<tr>
<th>IN-HOUSE PIPELINE</th>
<th>DISCOVERY</th>
<th>PRE-CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>STATUS &amp; EXPECTED MILESTONES</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEN-009 1st Generation Neoantigen Cancer Vaccine</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>Peptide + adjuvant vaccine</td>
</tr>
<tr>
<td>GEN-010 2nd Generation Neoantigen Cancer Vaccine</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>Proprietary vaccine modality</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PARTNERING</th>
<th>DISCOVERY</th>
<th>PRE-CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>STATUS &amp; EXPECTED MILESTONES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shared Antigen Cancer Vaccines</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>Exploring ATLAS® partnering opportunities</td>
</tr>
<tr>
<td>Vaccines for Cancers of Viral Origin</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>Exploring ATLAS® partnering opportunities</td>
</tr>
</tbody>
</table>
Hemispherx Biopharma, Inc.

COMPANY PROFILE

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.

Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.

The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company’s Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name “Naturaferon”) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.

The Company exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

MANAGEMENT TEAM

- Thomas K. Equels, M.S. J.D. - Executive Vice Chairman, Chief Executive Officer, President
- Adam Pascale, CPA - Chief Financial Officer
- David R. Strayer, M.D. - Chief Scientific & Medical Officer
- Peter W. Rodino III, J.D. - Executive Director for Governmental Relations, General Counsel, Secretary
- Wayne Springate - Senior Vice President of Operations

PIPELINE

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Development Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampligen®</td>
<td>ME/CFS</td>
<td>NDA Active. Company in discussions with FDA to formulate path forward for potential approval</td>
</tr>
<tr>
<td>Ampligen®</td>
<td>Vaccine Adjuvant</td>
<td>Phase I/II - Research Collaboration with the University of Alabama</td>
</tr>
<tr>
<td>Ampligen®</td>
<td>Ovarian, Colorectal, and Peritoneal Cancers</td>
<td>Phase I/II - Sponsored by University of Pittsburgh</td>
</tr>
<tr>
<td>Ampligen®</td>
<td>Colorectal, Melanoma Cancer</td>
<td>Pre-clinical research collaboration with Georgia Regents University</td>
</tr>
<tr>
<td>Ampligen®</td>
<td>Renal Cell Carcinoma, Melanoma Cancers</td>
<td>Phase I/II Research Collaboration with Hahnemann University</td>
</tr>
</tbody>
</table>
Hookipa Biotech AG

COMPANY PROFILE

Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology.

Our proprietary TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers.

We have completed the active phase of a Phase 1 trial of a Vaxwave®-based vaccine against cytomegalovirus (CMV) and are finalizing clinical development plans for TheraT® in Human Papilloma Virus (HPV)-related head and neck cancers.

MANAGEMENT TEAM

- Joern Aldag – Chief Executive Officer
- Reinhard Kandera – Chief Financial Officer
- Daniel Pinschever – Chief Scientific Officer
- Igor Matushansky – Global Head, Research and Development
- Vera Baumgartl-Strasser – Head of Licensing & Grant Management
- Andy Hwang – Head of Clinical Program and Operations Logistics
- Heidi Buchinger – Head of Regulatory Affairs
- Anders Lilja – Vice President Technical Development
- Tony Melckenbeek – Vice President Finance & Human Resources
- Torsten Mummenbrauer – Senior Vice President Business Development & Licensing
- Klaus Orlinger – Vice President Research

PIPELINE

Hookipa is committed to responsibly developing critical programs where TheraT® and Vaxwave® can make the biggest difference for the most people. Our science and technologies have demonstrated the possibility of highly potent antibody and T cell responses while maintaining safety, even with repeated administrations.

<table>
<thead>
<tr>
<th>COMPOUND</th>
<th>INDICATION</th>
<th>TARGET/ANTIGEN</th>
<th>DISCOVERY</th>
<th>PRE-CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB-101 VAXWAVE®</td>
<td>CYTOMEGALOVIRUS</td>
<td>GB/PPGS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RESEARCH VAXWAVE®</td>
<td>HEPATITIS B</td>
<td>HBc/HBc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HB-201 HETEROLOGOUS TI ERAT®</td>
<td>HPV- HEAD/NECK CANCER</td>
<td>HPV-16/18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HB-301 HETEROLOGOUS TI ERAT®</td>
<td>PROSTATE CANCER</td>
<td>PSA/PSA/PSMA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RRSSEARCH 101 TI ERAT®</td>
<td>NOT DISCLOSED</td>
<td>NOVEL ANTIGEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

www.sachsforum.com
Immunicum AB

COMPANY PROFILE

Immunicum is developing novel immuno-oncology therapies against a range of solid tumors. The approach is based on allogeneic dendritic cells that are designed to stimulate a personalized anti-tumor immune response in each patient. The Company’s lead compound, ilixadencel, is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer, and gastrointestinal stromal tumors. Ilixadencel combines the best aspects of two approaches: a cell-based, cost-effective and off-the-shelf immune enhancer that when injected intratumorally is capable of triggering a highly specific and potentially long-lasting immune reaction against tumor cells throughout the body.

MANAGEMENT TEAM

- Carlos de Sousa – Chief Executive Officer
- Peter Suenaert – Chief Medical Officer
- Michaela Gertz – Chief Financial Officer
- Alex Karlsson-Parra – Chief Scientific Officer
- Sharon Longhurst – Head of CMC
- Margareth Jorvid – Head of Regulatory and QA
- Sijme Zeilemaker – Senior Director Business Development

PIPELINE

Immunicum is focused on demonstrating the therapeutic value of ilixadencel through a rigorous clinical program led by the ongoing Phase II study in renal cell carcinoma. Immunicum has gathered encouraging results in trials conducted to date and will seek to further substantiate the potential for ilixadencel to help treat cancer patients as a component of either current standard of care or other combination treatment.

The Company has also defined additional opportunities that are currently in research and preclinical evaluation, including SUBCUVAX®. These programs are listed in the Development Programs.

<table>
<thead>
<tr>
<th>Ilixadencel IM-201</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ilixadencel IM-102</td>
<td>Liver</td>
</tr>
<tr>
<td>Ilixadencel IM-103</td>
<td>GIST</td>
</tr>
<tr>
<td>Ilixadencel IM-202 Head and Neck</td>
<td>Starting patient enrollment 2H2018</td>
</tr>
<tr>
<td>Ilixadencel IM-202 Lung</td>
<td>Starting patient enrollment 2H2018</td>
</tr>
<tr>
<td>Ilixadencel IM-202 Gastric</td>
<td>Starting patient enrollment 2H2018</td>
</tr>
<tr>
<td>SUBCUVAX/Adenovirus vector</td>
<td>TBD</td>
</tr>
<tr>
<td>CD70</td>
<td>TBD</td>
</tr>
</tbody>
</table>
Immunovaccine, Inc.

COMPANY PROFILE

Our technology provides the foundation of our Company and underscores the novel benefits of our product candidates across multiple therapeutic markets. Our human immune system is bombarded with countless messages and directives at any given moment. The key, we believe, is making sure that the right directives get through, safely and efficiently, to help our body do what it is already designed to do: fight serious diseases.

The technology behind our unique delivery platform can help to get the messages across, by promoting the active uptake and extending the delivery time to the immune system. Our formulations provide a simple but elegant solution to delivering the right messages, and helping to make sure they are received and acted upon, by our immune system.

Through partnerships with pharmaceutical and biotech leaders, we are leveraging the unique capabilities of platform to develop innovate therapies with potential to mobilize the power of the immune system in a more rapid, robust and sustained fashion. We work with a sense of purpose, using the best science and drug development practices to address urgent unmet medical needs in cancer and other diseases.

With three candidates already in clinical trials and several more at the precipice, we are committed to building a company that can deliver value for our shareholders, patients and communities.

MANAGEMENT TEAM

- Frederic “Fred” Ors - Chief Executive Officer
- Pierre Labbé - Chief Financial Officer
- Gabriela Nicola Rosu, MD - Chief Medical Officer
- Joseph Sullivan - Senior Vice President, Business Development
- Stephan Fiset - Vice President, Clinical Research
- Leeladhar Sammatur - Vice President, Product Development & Manufacturing
- Marianne Stanford, PhD - Vice President, Research
- Annie Tanguay - Vice President, Quality and Regulatory

PIPELINE

### IMMUNO-ONCOLOGY

<table>
<thead>
<tr>
<th>Indication</th>
<th>Candidate</th>
<th>Progress</th>
<th>Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovarian</td>
<td>DPKx-xCT &amp; mCPA + IDO1 Inhibitor</td>
<td>Phase I</td>
<td>Preclinical - MDAnderson Cancer</td>
</tr>
<tr>
<td></td>
<td>DPKx-xCT &amp; mCPA + anti-PD-1</td>
<td>Phase I</td>
<td>Preclinical - MDAnderson Cancer</td>
</tr>
<tr>
<td>ER- related</td>
<td>DPKx-xCT &amp; mCPA + anti-PD-1</td>
<td></td>
<td>Preclinical - MDAnderson Cancer</td>
</tr>
<tr>
<td>HPV-related Cancers</td>
<td>UPA-62 + NVG124</td>
<td></td>
<td>Preclinical - MDAnderson Cancer</td>
</tr>
</tbody>
</table>

### INFECTIOUS DISEASES

<table>
<thead>
<tr>
<th>Indication</th>
<th>Candidate</th>
<th>Progress</th>
<th>Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV</td>
<td>LMP1-kSV</td>
<td>Phase I</td>
<td>Completed</td>
</tr>
</tbody>
</table>
ISA Pharmaceuticals B.V.

COMPANY PROFILE

ISA Pharmaceuticals is a privately held company based in the Netherlands. It focuses on the development of rationally designed, fully synthetic immunotherapeutics for the treatment of cancer and persistent viral infections. ISA's development platform is based on its proprietary SLP® (synthetic long peptide) and AMPLIVANT® technologies. The platform is broadly applicable and suitable for a multitude of targets and product opportunities.

The company has established its development platform based on insight into the exact mechanism of action and the immunopharmacology of its immunotherapeutics. Various clinical trials up to completion of Phase II have demonstrated the safety, tolerability and clinical efficacy of SLP® compounds, thereby providing proof-of-concept.

The company was founded in 2004 by Aglaia Oncology Fund with Leiden University Medical Center (LUMC) as its primary research partner.

MANAGEMENT TEAM

- Gerben Moolhuizen - Chief Executive Officer
- Cornelis Melief, Ph.D. - Chief Scientific Officer
- Dr. Leon Hooftman - Chief Medical Officer
- Willem-Jan Krebber - Chief Operating Officer

PIPELINE

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Pre clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISA101b (HPV16)</td>
<td>Cervical Cancer</td>
<td></td>
<td>Cemiplimab (apD1) combo (start 2018)</td>
<td></td>
<td></td>
<td>REGENERON</td>
</tr>
<tr>
<td></td>
<td>SCCHN (IL)</td>
<td></td>
<td>Cemiplimab (apD1) combo (start 2018)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SCCHN (IL, IST)</td>
<td></td>
<td>MDACC/Utomilumab (4-1BB) combo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISA201 (HPV16)</td>
<td>H&amp;N/Cervical Cancer (Amplivent conjugates, IST)</td>
<td></td>
<td>HESPECTA – ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISA203 (PRAME)</td>
<td>Multiple cancer indications, incl glioblastoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISA204 (HBV)</td>
<td>Chronic Hepatitis B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>On-demand</td>
<td>Target orphan disease – other; MyISA® (neo-antigens)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Lycera

COMPANY PROFILE

Lycera is a private biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer. Based on successful progress of its world-class R&D platform, Lycera has advanced two programs into clinical development. Lycera’s most advanced wholly owned in cancer immunotherapy focuses on oral, selective RORγ agonists. The retinoic acid-related orphan receptor-gamma t (RORγt) is a nuclear receptor transcription factor that acts as a immune cell master control switch driving the generation and function of Th17 (helper T-cells) and Tc17 (cytotoxic) immune cells. Lycera’s clinical stage RORγ agonist, LYC-55716, combines multiple anti-tumor mechanisms into a single therapeutic by modulating gene expression to reprogram immune cells for improved function, as well as decrease immunosuppressive mechanisms. LYC-55716 has completed Phase 1 single agent clinical studies, demonstrating a well tolerated profile, disease stabilization in a subset of patients as well as a confirmed partial response in a patient with advanced non-small cell lung cancer which did not respond to checkpoint inhibitor or combination chemotherapy. LYC-55716 is currently in a Phase 2a study with 6 cohorts of patients with advanced solid tumors as well as in a Phase 1b combination study in non-small cell lung cancer in combination with anti-PD-1. The company is also advancing a wholly owned, oral, gut- directed ATPase modulator, designated LYC-30937-EC, for the treatment of autoimmune disease. Additionally early stage research programs are focused on advancing differentiated oral small molecules for novel targets in immuno-oncology. Lycera has an exclusive strategic collaboration with Celgene Corporation to advance Lycera’s proprietary pipeline for cancer and immune-mediated diseases.

MANAGEMENT TEAM

- Paul Sekhri - President and CEO
- Bruce A. Goldsmith, Ph.D. - Chief Operating Officer
- Alex G. Howarth - Chief Financial Officer
- H. Jeffrey Wilkins, M.D. - Chief Medical Officer
- Laura L. Carter, Ph.D. - Senior Vice President, Biology
- JoAnn Scatina, Ph.D. - Senior Vice President, Preclinical Development
- Peter L. Toogood, Ph.D. - Senior VP, Chemistry and Chemical Biology

PIPELINE

STAGE OF DEVELOPMENT

<table>
<thead>
<tr>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>LYC-30937 Enteric Coated (ATPase modulator)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ulcerative Colitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate Plaque-type Psoriasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LYC-55716 (RORγ agonist)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solid Tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Targets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immuno-Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

www.sachsforum.com
**Madison Vaccines Incorporated (MVI)**

**COMPANY PROFILE**

MVI is a clinical stage biopharmaceutical company developing active immunotherapies as monotherapy and in combination with anti-PD-1, for men with all stages of prostate cancer (PC). MVI is currently completing three clinical trials, using two plasmid DNA vaccines encoding PAP (MVI-816) and the androgen receptor (MVI-118). These trials include a fully enrolled placebo-controlled Phase 2 trial in biochemically-recurrent, hormone-sensitive prostate cancer. A pilot Phase 1/2 trial of MVI-816 + Keytruda® has revealed positive clinical signals in metastatic, castrate-resistant PC, including PSA responses and radiographic tumour regressions in patients with MSI(-) disease. A Phase 1 trial of MVI-118, in men with mHSPC who were initiating ADT, is also fully enrolled. MVI DNA plasmids are stable, off-the-shelf therapies, manufactured at low cost, and delivered by simple intradermal injection. MVI active immunotherapies represent an affordable and reimbursable platform for combination with PD-1 blockade, a critical consideration for bringing the benefits of immunotherapy to men with prostate cancer in a cost-constrained US health care system. MVI has 4 new planned clinical trials for 2018 and 2019, and is seeking full collaborative partnerships and investors to enable major proof-of-concept trials.

**MANAGEMENT TEAM**

- Richard Lesniewski, PhD, President and CEO
- Douglas McNeel, MD, PhD, CMO

**PIPELINE**

![Pipeline Diagram]
**Medicenna Therapeutics, Corp.**

**COMPANY PROFILE**

Our most advanced program, MDNA55, specifically targets the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna’s lead IL4-EC, MDNA55 is currently enrolling patients in a Phase 2b clinical trial for rGBM at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA.

Unlike most other cancer therapies, Medicenna’s IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment (TME), offering a unique treatment paradigm for a large majority of cancer patients.

Our approach to treat brain and other aggressive cancers received strong validation by a recent award of a $14.1M non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The treatment plan for the MDNA55 clinical trial includes our IL4R targeted drug MDNA55, precision image-guided convection enhanced delivery (CED) and real-time monitoring of drug distribution to ensure optimal delivery of the drug.

Treatment involves direct one-time intra-tumoral infusion of MDNA55 using CED. Image guided CED provides intra-tumoral delivery with sub-millimeter precision and real-time monitoring ensures uniform distribution of MDNA55 into the brain tumor and its infiltrative edges. We believe that this personalized approach by-passes the blood brain barrier (BBB), avoids potential systemic side effects and has the potential to reduce the risk of tumor recurrence – problems that have continued to plague this difficult to treat disease.

In addition to brain cancers, the IL4R is a marker for highly aggressive forms of solid and blood tumors affecting more than a million new cancer patients every year. The IL4/IL4R bias is known to play a central role in the establishment of a robust immunosuppressive tumor micro-environment (TME), is expressed by cancer stem cells and is generally associated with poor survival outcomes. MDNA55 and Medicenna’s next generation fully human IL4-EC platform (MDNA57) have the potential to mature into an important class of treatments addressing large unmet needs in oncology.

**MANAGEMENT TEAM**

- Fahar Merchant, PhD, - Chairman, President and CEO
- Elizabeth Williams - CPA, CA, Chief Financial Officer
- Martin Bexon - MD, Head of Clinical Development
- Rosemina Merchant - MESc, Chief Development Officer
- Shafique Fidai, PhD, Head of Discovery and Corporate Development
Numab Therapeutics AG

COMPANY PROFILE

Numab is a biopharmaceutical company specializing in the discovery and development of next-generation bi- and multi-specific antibodies for the treatment of cancer and auto-immune diseases. Our trispecific lead immuno-oncology product ND021 targets all PDL1-positive tumors and has the potential for superior safety and efficacy when compared to first generation checkpoint modulators (such as PD1 blockers) and combinations thereof. ND021 combines two validated mechanism of action in one molecule and restricts its activity to the tumor microenvironment. Our plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics.

MANAGEMENT TEAM

- David Urech - CSO & Co-CEO
- Oliver Middendorp - CBO & Co-CEO
- Peter Lichtlen - Chief Medical Officer
- Tea Gunde - Chief Research Officer
- Sebastian Meyer - Chief Operating Officer
- Roland Helfenstein - Chief Financial Officer

PIPELINE
OSE Immunotherapeutics

COMPANY PROFILE

OSE Immunotherapeutics (Nantes – ISIN : FR0012127173 ; Mnemo : OSE) was created in May 2016 through the merger of OSE Pharma, an immuno-oncology company developing specific immunotherapy activating T lymphocytes, and Effimune, a biotechnology company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.

OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body’s immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation.

These new generation products are optimized to better target key receptors of the immune response’s activation or regulation, thus allowing for longer therapeutic effects.

OSE Immunotherapeutics is specialized in the immune system regulation and activation technologies. The company relies upon its international and complementary team of experts involved in the research and optimisation of drug candidates, pharmaceutical development and drug registration.

The company’s strategy is based on the development of a balanced product portfolio with a diversified risk profile, and innovative drug candidates in immuno-oncology, autoimmune diseases and transplantation.

OSE Immunotherapeutics is managed by an experienced and well recognised team of health professionals, including the co-founders of both OSE Pharma and Effimune.

At present, OSE Immunotherapeutics has approximately 30 collaborators, full time employees and specialist consultants, all supported by international experts in immunology. Our high-level team is committed to optimizing R&D and progressing the clinical development of the company’s programs in immune regulation and activation to advance the projects towards the last clinical phase before registration.

The company is listed on Euronext Paris. The Head Office is located in Nantes (22, boulevard Benoni Goullin, 44200 Nantes), with teams based in Nantes and Paris (Pépinière Paris Santé Biotech, 29, rue du Faubourg Saint-Jacques, 75014 Paris).

MANAGEMENT TEAM

- Alexis Peyroles - Chief Executive Officer
- Dominique Costantini - Chairman and Director of Early Development
- Maryvonne Hiance - Vice Chairman
- Bernard Vanhove - Chief Operating Officer, Director of R&D and International Scientific Collaborations
Selecta Biosciences, Inc.

COMPANY PROFILE

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts.

MANAGEMENT TEAM

• Werner Cautreels, Ph.D. - President and CEO
• Lloyd Johnston, Ph.D. - Chief Operating Officer and Senior Vice President, Research and Development
• Takashi Kei Kishimoto, Ph.D. - Chief Scientific Officer
• David Abraham, J.D. - General Counsel, Chief Compliance Officer and Corporate Secretary
• Earl Sands, M.D. - Chief Medical Officer
• John Leaman, M.D. - Chief Financial Officer and Head of Corporate Strategy
• Stephen Smolinski - Chief Commercial Officer
• Dmitry Ovchinnikov, Ph.D. - Managing Director, SelectaRUS, LLC

PIPELINE

Selecta is developing a range of product candidates for patients with rare and serious diseases that utilize SVP-Rapamycin, the company’s proprietary immune tolerance agent, to prevent the formation of ADAs that might otherwise compromise the medication’s efficacy and safety.
Selvita S.A.

COMPANY PROFILE

Selvita is one of the largest drug discovery companies in Europe engaged in the research and development of breakthrough small molecules therapies in oncology. The company also have integrated drug discovery services division. Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland and foreign offices located in Greater Boston Area, San Francisco Bay Area and Cambridge, UK. Selvita employs over 470 people including 150 with PhD.

The most advanced Selvita’s program is SEL24, a dual PIM/FLT3 kinase inhibitor, which has entered the clinic in March 2017, and was subsequently licensed to Menarini Group.

The second most advanced program is SEL120, a first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer is currently developed in partnership with The Leukemia and Lymphoma Society.

Selvita Early Discovery programs include: Immunooncology platform, Epigenetic platform, program targeting metabolic abnormalities in cancer, as well as an early discovery stage programs in the area of protein kinases.

The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Merck, H3 Biomedicine, Nodthera Therapeutics, as well as Menarini Group and The Leukemia and Lymphoma Society.

MANAGEMENT TEAM

• Paweł Przewieźlikowski – Chief Executive Officer
• Krzysztof Brzózka – Executive Vice President, Chief Scientific Officer
• Bogusław Sieczkowski – Executive Vice President, Chief Operating Officer
• Steffen Heeger – Chief Medical Officer
• Mirosława Zydron – Member of the Management Board, Director of Chemistry Department
• Miłosz Gruca – Member of the Management Board, Director of Biology Department
• Edyta Jaworska – Member of the Management Board

PIPELINE

<table>
<thead>
<tr>
<th>PROGRAM NAME</th>
<th>TARGETS</th>
<th>INDICATION</th>
<th>DISCOVERY &amp; PRECLINICAL</th>
<th>CLINICAL DEVELOPMENT</th>
<th>PARTNER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted Therapies Platform</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEL14</td>
<td>PI3K/VEGFR FENES</td>
<td>Hemangiosarcoma, Miaogianglioma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEL12</td>
<td>CDK9/STAT5</td>
<td>Leukemia, lymphoma, myelodysplasias</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kinase Inhibitor Platform</td>
<td>Non-small cell lung cancer, breast cancer</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kinase Inhibitor Collaboration</td>
<td>Non-small cell lung cancer, breast cancer</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Epigenetics</td>
<td>Non-small cell lung cancer, breast cancer,</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Metabolism and Immunomodulation Platform</td>
<td>Metabolic abnormalities in cancer</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Immunology/Sarcoma</td>
<td>Akt, Lck, ErbB2</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology Platform</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collaboration of Brain/Immunology Regulators</td>
<td>NF-κB</td>
<td>Inflammation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunohematology Platform</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TapImmune, Inc.

COMPANY PROFILE

TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company’s peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company’s technologies may be used as stand-alone medications or in combination with other treatment modalities.

TapImmune is advancing two clinical stage T-cell vaccine candidates in multiple Phase II and Phase Ib/Ila clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from FDA Fast Track and Orphan Disease Designation. The company is working in collaboration with industry and clinical leaders including Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca.

MANAGEMENT TEAM

- Peter L. Hoang - President & CEO
- Glynn Wilson Ph.D - Chairman & Strategic Advisor
- Richard Kenney, MD, FACP - Acting Chief Medical Officer
- Michael J. Loiacono - CFO
- Robert Z. Florkiewicz - Sr. Director of Molecular Biology & Virology
- Elizabeth Donnelly - Director of Administration

FDA/Pipeline

<table>
<thead>
<tr>
<th>TPIV200: Folate Receptor-Alpha</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ovarian Cancer</strong></td>
</tr>
<tr>
<td>Platinum Sensitive - Efficacy in Maintenance Therapy: Enrolling</td>
</tr>
<tr>
<td>Collaborators/Sponsors: TapImmune, AstraZeneca, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Platinum Resistant - Efficacy in Combination Therapy: Open</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TPIV100/110: HER2/neu</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HER2+ Breast Cancers</strong></td>
</tr>
<tr>
<td>Combination Therapy: 2018 IND</td>
</tr>
<tr>
<td>Collaborators/Sponsors: TapImmune, Mayo Clinic, Department of Defense</td>
</tr>
<tr>
<td>Ductal Carcinoma in Situ: 2018</td>
</tr>
</tbody>
</table>

ADDRESS
5 West Forsyth Street
Suite 200
Jacksonville, FL 32202
United States

WEBSITE
www.tapimmune.com

PHONE
+1 904 862 6490

E-MAIL
investor.relations@tapimmune.com

COMPANY TYPE
Public

TICKER
[NASDAQ:TPIV]

SECTOR
Immuno-Oncology

FOUNDED
1991
Triumvira Immunologics, Inc.

COMPANY PROFILE

Triumvira Immunologics, Inc. is a preclinical-stage immunotherapy company developing an expanding pipeline of novel T cell therapies for solid and liquid cancers. Triumvira’s T cell therapies are based on the company’s proprietary T cell Antigen Coupler (TAC) technology poised to deliver safer and more efficacious therapies than current cancer treatments such as chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Grounded in a deep understanding of immunology and drug development, our international team is committed to initiating clinical testing of its lead therapeutic candidate CD19-TAC01 in lymphoma patients in early 2019 followed by two candidates to treat solid tumors.

Triumvira is led by Dr. Paul Lammers, CEO & President, and an experienced management team with operational, clinic and product development expertise. Spanning the United States and Canada, our headquarters are in Austin, Texas, and our research facilities are in Hamilton, Ontario.

MANAGEMENT TEAM

- Paul Lammers, MD, MSc, - President and Chief Executive Officer
- Jonathan Bramson, PhD, - Chief Scientific Officer
- Sabine Chlosta - MD, PhD, - Chief Medical Officer
- Donna Rill - CTO
- Jon Irvin - Vice President, Finance

PIPELINE

![Pipeline Diagram](Image)
VLP Therapeutics

COMPANY PROFILE

VLP Therapeutics was established in 2013 with a mission to create next-generation virus-like particles to transform traditional vaccine therapies. We are focusing on cancer and infectious disease vaccines. VLP Therapeutics modifies viruses to target cells in two ways: 1) delivery of substantial antigen on the surface of the virus; and 2) direct insertion of genetic material inside the virus. Our virus-like particles have proven to be highly immunogenic in multiple animal models and we anticipate being in a human trial in 2018. The company is headquartered in Gaithersburg, Maryland.

MANAGEMENT TEAM

• Dr. Wataru Akahata, Ph.D., Co-Founder, CEO and CSO
• Jacob Licht, COO
• George Moonsammy, MA, PhD., Director, Clinical & Regulatory Affairs

PIPELINE

<table>
<thead>
<tr>
<th>Platform</th>
<th>Indication</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td>i-αVLP</td>
<td>Malaria</td>
<td>CSP surface protein</td>
<td></td>
<td>Phase I/IIa in 2018</td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td>Immune checkpoints</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td>Viral Antigens</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer's</td>
<td>Immune protein</td>
<td></td>
<td>Outlicensed to Cynk, 2016</td>
</tr>
<tr>
<td>Non-platform</td>
<td>Zika</td>
<td>VLP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dengue</td>
<td>VLP (Serotypes 1-4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
BerGenBio ASA is a phase II clinical stage biopharmaceutical company focused on developing selective AXL inhibitors as a potential cornerstone for cancer therapy.

BerGenBio’s phase II programme is focused on establishing proof of concept that its lead product bemcentinib, a first-in-class selective inhibitor of the receptor tyrosine kinase AXL, may reverse and prevent resistance to immune, targeted and chemotherapy thus holding promise as a potential future cornerstone to cancer therapy. Six phase II trials are ongoing across NSCLC, TNBC, AML and Melanoma, indications with high unmet medical need.

The company is also developing an AXL antibody slated to enter the clinic in 2018 and has several immunomodulatory small molecule programmes in pre-clinical development.
SUPPORTING ORGANISATIONS

BioPartner

www.biopartner.co.uk

BioPartner is an independent, government-accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner’s delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartner Programme, members receive extra benefits and support to effectively trade overseas.

Biotechgate

www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Bio-tech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

Citigate Dewe Rogerson

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world’s leading strategic communications consultancies. Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo - NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m). Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics ($3.6m - Series A). Recent M&A: Heptares (up to $400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).
Edison

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison’s largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

FreeMind

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations. FreeMind’s knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist in making non-dilutive funding a key tool in a long-term financial strategy.

Instinctif Partners

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.
Swiss Biotech

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, Basel Area, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Tiberend Strategic Advisors, Inc.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies:

1. To enhance valuation
2. To build visibility for partnerships and strategic alliances
SACHS ASSOCIATES

www.sachsforum.com

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on biopharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS FOLLOWS:

ONLINE ONE-2-ONE MEETING SYSTEM

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides all delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

CUTTING EDGE CONTENT WITH EMINENT SPEAKERS

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the company has attracted very senior scientific and business personalities as speakers at its events.

SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS

Sachs Associates has developed an extensive knowledge of the key individuals operating within the global bio-tech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your company’s position in this market. Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor-made for each client, allowing your organisation to gain the most out of attending our industry driven events.

THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:

- Conference Sponsor – including workshops and social events
- Exhibition Stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities, please call Silvia Kar on +44 203 463 4890 or email Silvia@sachsforum.com.